Vimian Group AB
STO:VIMIAN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.7617
46.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vimian Group AB
Total Equity
Vimian Group AB
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Total Equity
€667.5m
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Total Equity
kr251.1m
|
CAGR 3-Years
31%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Total Equity
kr2.1B
|
CAGR 3-Years
27%
|
CAGR 5-Years
29%
|
CAGR 10-Years
28%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Total Equity
kr3.1B
|
CAGR 3-Years
237%
|
CAGR 5-Years
185%
|
CAGR 10-Years
75%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Total Equity
kr353.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Total Equity
kr10.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Vimian Group AB
Glance View
Vimian Group AB operates as an animal health company. The company is headquartered in Stockholm, Stockholm and currently employs 1,068 full-time employees. The company went IPO on 2021-06-18. The firm is a parent company of the group of companies operating with a purpose of improving animal health through science and technology. The Group delivers solutions to veterinary professionals, labs and pet parents around the world. The purpose of Vimian Group is to unite companies in selected niches of animal health and help them grow faster. The firm invests in innovation and new technologies to advance veterinary medicine. The Group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to its networks, advisory services, infrastructure and capital.
See Also
What is Vimian Group AB's Total Equity?
Total Equity
667.5m
EUR
Based on the financial report for Sep 30, 2024, Vimian Group AB's Total Equity amounts to 667.5m EUR.
What is Vimian Group AB's Total Equity growth rate?
Total Equity CAGR 3Y
24%
Over the last year, the Total Equity growth was 25%. The average annual Total Equity growth rates for Vimian Group AB have been 24% over the past three years .
You don't have any saved screeners yet
